Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein

Clinical and Vaccine Immunology

Volumn 18, Issue 6, 2011, Pages 1002-1014

  Lucidarme, Jay ^a   Tan, Lionel ^b   Exley, Rachel M ^b   Findlow, Jamie ^a   Borrow, Ray ^a,c   Tang, Christoph M ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; LIPOPROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONAL VARIATION; CONTROLLED STUDY; DNA FLANKING REGION; FRAMESHIFT MUTATION; GENE LOSS; LIGAND BINDING; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; STRAIN IDENTIFICATION;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; FRAMESHIFT MUTATION; GENE DELETION; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; VIRULENCE FACTORS;

EID: 79958017248     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00055-11     Document Type: Article

References (52)

1. Bambini, S., et al. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.
2. Bennett, J. S., et al. 2010. Independent evolution of the core and accessory gene sets in the genus Neisseria: insights gained from the genome of Neisseria lactamica isolate 020-06. BMC Genomics 11:652.
3. Bentley, S. D., et al. 2007. Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. PLoS Genet. 3:e23.
4. Blom, A. M., T. Hallstrom, and K. Riesbeck. 2009. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol. Immunol. 46:2808-2817.
5. Brandtzaeg, P., et al. 1989. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J. Infect. Dis. 159:195-204.
6. Brehony, C., D. J. Wilson, and M. C. Maiden. 2009. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155:4155-4169.
7. Cartwright, K. A., J. M. Stuart, D. M. Jones, and N. D. Noah. 1987. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol. Infect. 99:591-601.
8. Chung, G. T., et al. 2008. Complete genome sequence of Neisseria gonorrhoeae NCCP11945. J. Bacteriol. 190:6035-6036.
9. Claus, H., J. Elias, C. Meinhardt, M. Frosch, and U. Vogel. 2007. Deletion of the meningococcal fetA gene used for antigen sequence typing of invasive and commensal isolates from Germany: frequencies and mechanisms. J. Clin. Microbiol. 45:2960-2964.
10. Davila, S., et al. 2010. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 42:772-776.
11. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4:359-395.
12. Findlow, J., et al. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.
13. Fletcher, L. D., et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100.
14. Giuliani, M. M., et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.
15. Gray, S. J., et al. 2006. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55:887-896.
16. Hammerschmidt, S., et al. 1994. Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Mol. Microbiol. 11:885-896.
17. Hammerschmidt, S., et al. 1996. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol. Microbiol. 20:1211-1220.
18. Harris, S. L., et al. 2011. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum. Vaccin. 7:68-74.
19. Harrison, L. H., et al. 2010. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era - United States, 2000-2005. J. Infect. Dis. 201:1208-1224.
20. Harrison, L. H., C. L. Trotter, and M. E. Ramsay. 2009. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2):B51-B63.
21. Jarva, H., S. Ram, U. Vogel, A. M. Blom, and S. Meri. 2005. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol. 174:6299-6307. (Pubitemid 40663822)
22. Joseph, B., et al. 2010. Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence. J. Bacteriol. 192:5363-5377.
23. Kugelberg, E., et al. 2010. The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease. PLoS One 5:e9413.
24. Lewis, L. A., et al. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6:e1001027.
25. Lewis, L. A., et al. 2008. Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect. Immun. 76:339-350.
26. Lucidarme, J., et al. 2009. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J. Clin. Microbiol. 47:3577-3585.
27. Lucidarme, J., et al. 2010. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin. Vaccine Immunol. 17: 919-929.
28. Madico, G., et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510. (Pubitemid 43939163)
29. Maiden, M. C., et al. 2008. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197:737-743.
30. Martin, D., N. Cadieux, J. Hamel, and B. R. Brodeur. 1997. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185:1173-1183.
31. Mascioni, A., et al. 2009. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J. Biol. Chem. 284:8738-8746.
32. Masignani, V., et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
33. Murphy, E., et al. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389.
34. Newcombe, J., K. Cartwright, S. Dyer, and J. McFadden. 1998. Naturally occurring insertional inactivation of the porA gene of Neisseria meningitidis by integration of IS1301. Mol. Microbiol. 30:453-454.
35. Parkhill, J., et al. 2000. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404:502-506. (Pubitemid 30186893)
36. Peng, J., et al. 2008. Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. Genomics 91:78-87. (Pubitemid 350298396)
37. Rusniok, C., et al. 2009. NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis. Genome Biol. 10:R110.
38. Schneider, M. C., et al. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566-7575. (Pubitemid 43849060)
39. Schneider, M. C., R. M. Exley, S. Ram, R. B. Sim, and C. M. Tang. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15:233-240.
40. Schneider, M. C., et al. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893.
41. Schoen, C., et al. 2008. Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc. Natl. Acad. Sci. U. S. A. 105:3473-3478.
42. Schoen, C., H. Tettelin, J. Parkhill, and M. Frosch. 2009. Genome flexibility in Neisseria meningitidis. Vaccine 27(Suppl. 2):B103-B111.
43. Seib, K. L., et al. 2009. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect. Immun. 77:292-299.
44. Stephens, D. S., B. Greenwood, and P. Brandtzaeg. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196-2210. (Pubitemid 46977462)
45. Sutherland, T. C., P. Quattroni, R. M. Exley, and C. M. Tang. 2010. Transcellular passage of Neisseria meningitidis across a polarized respiratory epithelium. Infect. Immun. 78:3832-3847.
46. Tettelin, H., et al. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:1809-1815. (Pubitemid 30143964)
47. Uria, M. J., et al. 2008. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J. Exp. Med. 205:1423-1434.
48. van Deuren, M., P. Brandtzaeg, and J. W. van der Meer. 2000. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin. Microbiol. Rev. 13:144-166.
49. van Ulsen, P., L. Rutten, M. Feller, J. Tommassen, and A. van der Ende. 2008. Two-partner secretion systems of Neisseria meningitidis associated with invasive clonal complexes. Infect. Immun. 76:4649-4658.
50. Virji, M., K. Makepeace, and E. R. Moxon. 1994. Distinct mechanisms of interactions of Opc-expressing meningococci at apical and basolateral surfaces of human endothelial cells; the role of integrins in apical interactions. Mol. Microbiol. 14:173-184.
51. Yazdankhah, S. P., and D. A. Caugant. 2004. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol. 53:821-832.
52. Zipfel, P. F., and C. Skerka. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9:729-740.